Regarding IC50 values of BTZ estimated in this study (up to 21 nM, Table 2), a dose-reduction of BTZ while maintaining therapeutic efficacy through combination with low toxic YAK540 (class IIa HDACI) is a hypothesis worth being tested in further studies, including animal and clinical studies, to improve multiple myeloma, leukemia and especially AML treatment. This evidence concerns the gene CASC3 and AL amyloidosis.